A Phase 3 interventional study of S-1/Cisplatin and 5-FU/cisplatin in Gastric Cancer, sponsored by Taiho Oncology, Inc.. Completed at 33 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing tegafur in Stomach Neoplasms — 10 open to participants now, 11 under way, 1 of them phase 3. Tegafur · Stomach Neoplasms.
Among the 65 studies testing tegafur in Stomach Neoplasms, this one has the largest enrollment of the 64 interventional ones that give a count, is one of 3 that started in 2005, is one of 13 in phase 3, and was the 1st registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →10 of the 65 studies testing tegafur in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18–80
Jinbo Yue · Sites in China
Ages 18–75
Ruijin Hospital · Sites in China
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Tegafur: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 46 · Phase 3 17
First in 2001; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,053 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 62 across the 64 interventional studies. Of the 25 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Taiho Oncology, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.
14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd.: 1 open now, 1 under way, none of them phase 3. Of 12 finished, 6 (50%) have results posted.
Among the 14 studies in Stomach Neoplasms by Otsuka Holdings Co., Ltd., this one has the largest enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2005, is one of 8 in phase 3, and was the 3rd registered.
Otsuka Holdings Co., Ltd.’s Stomach Neoplasms studies by the year they started, since 1997.
3 of the studies testing tegafur in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07304258Hebei Medical UniversityA Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10 | 2026-12-31 |
| NCT06519591Ruijin HospitalSystemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis | 2027-01 |
| NCT05184803Asan Medical CenterA Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing tegafur in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 14 in Stomach Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, international, two-arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of S-1/cisplatin versus 5-FU/cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease. Patients will be randomly assigned (1:1) to S-1/cisplatin (experimental arm) or 5-FU/cisplatin (control arm). Patients will be stratified by number of metastatic sites (one vs. more than one), locally advanced or metastatic disease, prior adjuvant therapy (yes or no), measurable or non-measurable disease, and center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:
Has measurable or evaluable but non-, defined as follows:
Has adequate organ function as defined by the following criteria:
Exclusion Criteria:
Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if any of the following conditions are observed:
Has had a treatment with any of the following within the specified timeframe prior to study drug administration:
Has a serious illness or medical condition(s) including, but not limited to the following:
Is receiving concomitant treatment with drugs interacting with S-1. The following drugs are prohibited because there may be an interaction with S-1:
Is receiving concomitant treatment with drugs interacting with 5-FU:
Is receiving concomitant treatment with drugs interacting with cisplatin:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
Drug: S-1/Cisplatin
In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.
Drug: 5-FU/cisplatin
Drug pages: Tegafur · Gimeracil · Oxonic Acid · Cisplatin
In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1. Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
Drug pages: Fluorouracil · Cisplatin
In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
Median Survival
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient.
Time frame: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
Overall Response Rate (ORR)
The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions.
Time frame: Data cutoff was 07 March 2008 (12 months after last patient randomized).
Duration of Response (DR)
Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions.
Time frame: Data cutoff was 07 March 2008 (12 months after last patient was randomized).
Progression-free Survival (PFS)
The time from randomization to date of first documented PD or date of death, whichever occurred first.
Time frame: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
Time to Treatment Failure (TTF)
The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first.
Time frame: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
This multicenter study was conducted between May 18, 2005 and March 7, 2008 in 24 countries including the United States. Study centers were also located in Canada, Eastern and Western Europe, South America, Australia, and ex-Soviet Union block of nations.
| Milestone | S-1/Cisplatin | 5-FU/Cisplatin |
|---|---|---|
| Started | 527 | 526 |
| Completed | 521 | 508 |
| Not completed | 6 | 18 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Withdrew consent | 1 | 5 |
| Withdrew: Disease progression | 1 | 1 |
| Withdrew: Intercurrent illness | 0 | 1 |
| Withdrew: Investigator judgment | 0 | 1 |
| Withdrew: Randomization error/patient ineligible | 1 | 6 |
The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions.
| Percentage of patients in each group | S-1/Cisplatin | 5-FU/Cisplatin |
|---|---|---|
| Overall Response Rate (ORR) | 29.1 (24.7 to 33.8) | 31.9 (27.3 to 36.9) |
Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions.
| Months | S-1/Cisplatin | 5-FU/Cisplatin |
|---|---|---|
| Duration of Response (DR) | 6.5 (5.8 to 7.4) | 5.8 (5.5 to 6.1) |
The time from randomization to date of first documented PD or date of death, whichever occurred first.
| Months | S-1/Cisplatin | 5-FU/Cisplatin |
|---|---|---|
| Progression-free Survival (PFS) | 4.8 (4.0 to 5.5) | 5.5 (4.4 to 5.8) |
The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first.
| Months | S-1/Cisplatin | 5-FU/Cisplatin |
|---|---|---|
| Time to Treatment Failure (TTF) | 3.8 (3.7 to 4.0) | 3.8 (3.7 to 4.4) |
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient.
| Months | S-1/Cisplatin | 5-FU/Cisplatin |
|---|---|---|
| Median Survival | 8.6 (7.9 to 9.5) | 7.9 (7.2 to 8.5) |
Collected over From the start of study drug administration until 12 months after last patient randomized. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| S-1/Cisplatin | — | 257/521 (49.3%) | 514/521 (98.7%) |
| 5-FU/Cisplatin | — | 248/508 (48.8%) | 504/508 (99.2%) |
| Event | S-1/Cisplatin | 5-FU/Cisplatin |
|---|---|---|
| Disease progressionGeneral disorders | 53/521 | 34/508 |
| AnaemiaBlood and lymphatic system disorders | 33/521 | 31/508 |
| DehydrationMetabolism and nutrition disorders | 21/521 | 32/508 |
| Febrile neutropeniaBlood and lymphatic system disorders | 8/521 | 31/508 |
| NeutropeniaBlood and lymphatic system disorders | 8/521 | 31/508 |
| StomatitisGastrointestinal disorders | 3/521 | 24/508 |
| VomitingGastrointestinal disorders | 23/521 | 17/508 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/521 | 17/508 |
| Deep vein thrombosisVascular disorders | 5/521 | 17/508 |
| NauseaGastrointestinal disorders | 17/521 | 10/508 |
| Event | S-1/Cisplatin | 5-FU/Cisplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 321/521 | 342/508 |
| VomitingGastrointestinal disorders | 260/521 | 281/508 |
| NeutropeniaBlood and lymphatic system disorders | 149/521 | 240/508 |
| AnaemiaBlood and lymphatic system disorders | 229/521 | 234/508 |
| FatigueGeneral disorders | 205/521 | 200/508 |
| DiarrhoeaGastrointestinal disorders | 152/521 | 195/508 |
| AnorexiaMetabolism and nutrition disorders | 164/521 | 177/508 |
| Weight decreasedInvestigations | 148/521 | 164/508 |
| StomatitisGastrointestinal disorders | 33/521 | 153/508 |
| Mucosal inflammationGeneral disorders | 20/521 | 152/508 |
| Age, Continuous(Years) | S-1/Cisplatin | 5-FU/Cisplatin | Total |
|---|---|---|---|
| Baseline Measure Data (descriptive stats, median) | 59.0 (18 to 83) | 59.0 (18 to 85) | 59.0 (18 to 85) |
| Sex: Female, Male(Participants) | S-1/Cisplatin | 5-FU/Cisplatin | Total |
|---|---|---|---|
| Female | 139 | 161 | 300 |
| Male | 382 | 347 | 729 |
| Race (NIH/OMB)(Participants) | S-1/Cisplatin | 5-FU/Cisplatin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 6 | 10 |
| Asian | 4 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 7 | 12 |
| White | 447 | 438 | 885 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 61 | 53 | 114 |
| Body surface area (BSA) Categories(Participants) | S-1/Cisplatin | 5-FU/Cisplatin | Total |
|---|---|---|---|
| </=1.29 m2 | 4 | 5 | 9 |
| 1.30-1.49 m2 | 46 | 44 | 90 |
| 1.50-1.69 m2 | 118 | 147 | 265 |
| 1.70-1.89 m2 | 208 | 181 | 389 |
| 1.90-2.09 m2 | 114 | 93 | 207 |
| 2.10-2.29 m2 | 29 | 34 | 63 |
| >/=2.30 m2 | 2 | 4 | 6 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | S-1/Cisplatin | 5-FU/Cisplatin | Total |
|---|---|---|---|
| 0 | 226 | 200 | 426 |
| 1 | 295 | 308 | 603 |
| Tissue Type(Participants) | S-1/Cisplatin | 5-FU/Cisplatin | Total |
|---|---|---|---|
| Papillary adenocarcinoma | 15 | 15 | 30 |
| Tubular adenocarcinoma | 132 | 113 | 245 |
| Well-differentiated | 20 | 17 | 37 |
| Moderately-differentiated | 105 | 91 | 196 |
| Unknown | 7 | 5 | 12 |
| Poorly differentiated adenocarcinoma | 210 | 189 | 399 |
| Signet-ring cell carcinoma | 75 | 95 | 170 |
| Mucinous adenocarcinoma | 28 | 32 | 60 |
| Other | 97 | 94 | 191 |
| Adenocarcinoma NOS | 87 | 87 | 174 |
| Poorly differentiated cancer | 7 | 2 | 9 |
| Unknown/not specified | 1 | 1 | 2 |
| Other types | 2 | 4 | 6 |
| Anatomical Location of Primary Lesion(Participants) | S-1/Cisplatin | 5-FU/Cisplatin | Total |
|---|---|---|---|
| Stomach | 438 | 417 | 855 |
| Gastroesophageal junction | 82 | 88 | 170 |
| Stomach and gastroesophageal junction | 1 | 3 | 4 |
| Extent of Disease(Participants) | S-1/Cisplatin | 5-FU/Cisplatin | Total |
|---|---|---|---|
| Locally advanced | 23 | 20 | 43 |
| 1 metastatic site | 157 | 161 | 318 |
| >/=2 metastatic sites | 340 | 327 | 667 |
| Not assessed | 1 | 0 | 1 |
1 further baseline measures are reported on the registry.
The record gives a start of May 2005, a primary completion of Mar 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tegafur · Gimeracil · Oxonic Acid · Cisplatin · Fluorouracil